Phase 3 Prostate cancer trials recruiting now

All Prostate cancer trials, every phase

Other phases for Prostate cancer

Phase 3 Prostate cancer trials

• 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
  NCT05520255 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• 2 Ablative RadioTherapy Treatments for Prostate Cancer
  NCT04654338 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: Male · 1 location
• 4-aminopyridine Treatment for Nerve Injury
  NCT03701581 · Phase: Phase 2, Phase 3 · Ages: 45 Years to 75 Years · Sex: Male · 2 locations
• 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
  NCT07209878 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 298 locations
• A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
  NCT07241416 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
  NCT07311694 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
  NCT07365995 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 30 locations
• A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
  NCT06320067 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 18 locations
• A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
  NCT03258320 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 75 Years · Sex: Male · 2 locations
• A Study of Changes to Prostate Procedures
  NCT06986083 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 692 locations
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 330 locations
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 152 locations
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 173 locations
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 151 locations
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 281 locations
• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
  NCT07723248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
  NCT06629779 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 236 locations
• A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  NCT03851640 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
  NCT05613023 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 42 locations
• ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
  NCT04916613 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 95 locations
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 132 locations
• Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
  NCT02064673 · Phase: Phase 3 · Ages: 30 Years to 80 Years · Sex: Male · 1 location
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · 144 locations
• Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
  NCT06235697 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 57 locations
• Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
  NCT07260435 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 26 locations
• Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
  NCT06861192 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: Male · 1 location
• Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
  NCT04794777 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 5 locations
• Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
  NCT07548164 · Phase: Phase 3 · Ages: No age limits stated · Sex: Male · 8 locations
• Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
  NCT05956639 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
  NCT05983783 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: Male · 1 location
• Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
  NCT06112990 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
  NCT05786716 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 27 locations
• Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
  NCT06122584 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 18 locations
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 395 locations
• Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
  NCT07751133 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
  NCT06565247 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 2 locations
• Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
  NCT05116475 · Phase: Phase 3 · Ages: 18 Years to 120 Years · Sex: Male · 1 location
• Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
  NCT01492972 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 4 locations
• Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
  NCT05448547 · Phase: Phase 3 · Ages: 75 Years and older · Sex: Male · 26 locations
• Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
  NCT04833426 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 10 locations
• Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
  NCT05974774 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · 9 locations
• Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
  NCT06177015 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: Male · 1 location
• Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
  NCT07615101 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 2 locations
• Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)
  NCT06825091 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Long-term Better Than Short-term ADT With Salvage RT
  NCT04242017 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: Male · 3 locations
• Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
  NCT06717711 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Male · 2 locations
• Maximal Tumor Eradication for Oligometastatic Prostate Cancer
  NCT06972511 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• Measuring Oncological Value of Exercise and Statin
  NCT05796973 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
  NCT05352178 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
  NCT06585007 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
  NCT06780670 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · 81 locations
• PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
  NCT07426055 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
  NCT07426094 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
  NCT06274047 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 6 locations
• PSMA PET Combined With MRI for the Detection of PCa
  NCT07052214 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 18 locations
• PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
  NCT04642027 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 13 locations
• PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
  NCT03495427 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• PSMA-PET to Guide Prostatectomy
  NCT05381103 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 80 Years · Sex: Male · 1 location
• PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
  NCT03594760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
  NCT07333066 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 56 locations
• Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
  NCT06439225 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 14 locations
• Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
  NCT06056830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 31 locations
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
  NCT03903835 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 32 locations
• REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
  NCT06650579 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 4 locations
• Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
  NCT06625034 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 2 locations
• Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
  NCT07477626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 13 locations
• Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
  NCT07427043 · Phase: Phase 3 · Ages: 45 Years and older · Sex: Male · 2 locations
• SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
  NCT06945315 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
  NCT06205316 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 6 locations
• SRT Versus SRT+ADT in Prostate Cancer
  NCT05019846 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
  NCT07500701 · Phase: Phase 3 · Ages: 20 Years and older · Sex: Male · 1 location
• Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
  NCT06626022 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: Male · 9 locations
• Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
  NCT05781217 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 338 locations
• Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
  NCT06496581 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 25 locations
• Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
  NCT06563388 · Phase: Phase 3 · Ages: 1 Year and older · Sex: All (male and female) · 2 locations
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
  NCT06855277 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · 93 locations
• Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
  NCT06625970 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 6 locations
• Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
  NCT06754085 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 288 locations
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
  NCT07200830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 129 locations
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 413 locations
• Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
  NCT06470243 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 174 locations
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 210 locations
• The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
  NCT06520345 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 33 locations
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 337 locations
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
  NCT04423211 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 341 locations
• Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
  NCT06276465 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 4 locations
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
  NCT06282588 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 9 locations
• Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
  NCT03819101 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 30 locations
• Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
  NCT03769766 · Phase: Phase 3 · Ages: 40 Years to 89 Years · Sex: Male · 1 location
• Trop2-targeted immunoPET Imaging of Solid Tumors
  NCT06851663 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
  NCT07293585 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
  NCT04787744 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 20 locations
• Vitamin D for Prostate Endocrine Therapy
  NCT05838716 · Phase: Phase 3 · Ages: 50 Years and older · Sex: Male · 51 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.